Liver Disease News and Research RSS Feed - Liver Disease News and Research

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.
New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

New pill-only antiviral drug regimens could cure hardest-to-treat hepatitis C

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet. [More]
First systematic analysis indicates that about 1 in 3000 donors in England have HEV

First systematic analysis indicates that about 1 in 3000 donors in England have HEV

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around 1200 HEV-containing blood components (eg, red cells, platelets, and fresh frozen plasma) are likely to be transfused every year in England. [More]
Researchers provide global genotype prevalence estimates for HCV

Researchers provide global genotype prevalence estimates for HCV

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that genotype 1 is the most prevalent worldwide, with over 83 million patients infected of which one-third reside in East Asia. [More]
Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Clinicians and researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University will present new findings from eight abstracts at the International Federation of Head and Neck Oncologic Societies World Congress being held July 26 - July 30 in New York. [More]
RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities. [More]
Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

Unique bacterial biomarkers may help develop diagnostics, treatments for liver cirrhosis

ENTEROME Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, and with a strong focus on liver diseases, highlights the advanced online publication in Nature of a research paper describing the identification of a unique series of bacterial biomarkers that could provide new opportunities for the development of diagnostics and treatments for liver cirrhosis. [More]
Study: Slow walking, memory complaints may predict future dementia

Study: Slow walking, memory complaints may predict future dementia

A study involving nearly 27,000 older adults on five continents found that nearly 1 in 10 met criteria for pre-dementia based on a simple test that measures how fast people walk and whether they have cognitive complaints. [More]
Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014. [More]
$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

$1,000-a-pill hepatitis C drug boosts Gilead's fortunes

Sales of the new hepatitis C drug Sovaldi reached $3.5 billion in the second quarter, putting it on track to become one of the world's best-selling medicines and intensifying concerns about its costs. [More]
First Edition: July 24, 2014

First Edition: July 24, 2014

Today's headlines include more analysis of this week's conflicting appeals courts' decisions regarding a key part of the health law. [More]
New momentum: WHO welcomes progress in tackling viral hepatitis

New momentum: WHO welcomes progress in tackling viral hepatitis

On World Hepatitis Day, 28 July, WHO welcomes new progress in tackling one of the world's most serious diseases. Viral hepatitis - a group of infectious diseases known as hepatitis A, B, C, D, and E - affects millions of people worldwide, causing acute and chronic liver disease and killing close to 1.4 million people every year. [More]
Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Tackling hepatitis C: an interview with Gaston Picchio, Global Hepatitis Disease Area Leader at Janssen

Gaston Picchio outlines the major findings of the recent report published by The Economist Intelligence Unit (EIU): ‘Tackling hepatitis C: Moving towards an integrated policy approach’ [More]
Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

As a more sensitive maker of renal dysfunction Randox Cystatin C offers several advantages over traditional creatinine assays. [More]
Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. [More]
Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. [More]
Consumption of probiotics during 30 days helps diminish accumulation of fat in liver

Consumption of probiotics during 30 days helps diminish accumulation of fat in liver

Spanish scientists have demonstrated through an experiment on obese rats that the consumption of probiotics during thirty days helps diminish the accumulation of fat in the liver. [More]
Many liver transplant patients want to be involved in the decision of whether to accept the organ

Many liver transplant patients want to be involved in the decision of whether to accept the organ

A novel study reveals that more than half of liver transplant patients want to be informed of donor risk at the time a liver is offered for transplantation. Nearly 80% of those patients want to be involved in the decision of whether or not to accept the organ according to findings published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. [More]
Inappropriate expectations, lack of empathy play role in children with developmental disabilities

Inappropriate expectations, lack of empathy play role in children with developmental disabilities

Children with developmental disabilities are at higher risk for abuse and neglect from parents than children developing at a typical rate. [More]
Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. [More]
Telemedicine could improve quality of life of patients with chronic liver diseases

Telemedicine could improve quality of life of patients with chronic liver diseases

Although telemedicine could improve the quality of life of patients with chronic liver diseases, viable home care systems are still lacking. Scientists working on the EU-project "d-LIVER" mean to remedy this situation. Initial results have now been released. [More]